webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Gemcitabine-O-Si(di-iso)-O-Mc

  CAS No.:   Cat No.: BADC-00872   Purity: >98% 4.5  

Gemcitabine-O-Si(di-iso)-O-Mc is a drug-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker.

Gemcitabine-O-Si(di-iso)-O-Mc

Structure of

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin with Linker
Molecular Formula
C24H36F2N4O7Si
Molecular Weight
558.65
Shipping
Room temperature
Storage
Store at -20 °C, keep in dry and avoid sunlight.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Solubility
10 mm in DMSO
Shelf Life
0-4°C for short term (days to weeks), or -20°C for long term (months).
Shipping
Room temperature
Storage
Store at -20 °C, keep in dry and avoid sunlight.

Gemcitabine-O-Si(di-iso)-O-Mc is a synthetic derivative of the antineoplastic agent gemcitabine, meticulously crafted to elevate its efficacy and delivery. Here are four key applications of this innovative compound:

Chemotherapy: Gemcitabine-O-Si(di-iso)-O-Mc plays a pivotal role in chemotherapy regimens targeting a spectrum of cancers like pancreatic, lung, and breast cancer. Its advanced delivery system ensures optimized drug concentrations reach malignant cells, amplifying therapeutic effectiveness. This tailored approach not only fosters superior treatment outcomes but also holds the promise of mitigating adverse effects linked to conventional gemcitabine therapy.

Targeted Drug Delivery: By transforming gemcitabine into Gemcitabine-O-Si(di-iso)-O-Mc, researchers unlock the potential for tailored drug delivery systems. These systems precisely guide the drug to cancerous cells, minimizing harm to healthy tissues. Such targeted precision not only augments therapeutic efficacy but also diminishes systemic toxicity.

Drug Combination Studies: Exploration of Gemcitabine-O-Si(di-iso)-O-Mc in synergy with other chemotherapeutic agents unveils the potential for enhanced anticancer effects. Combining this derivative with complementary drugs may synergistically elevate overall efficacy and surmount resistance mechanisms.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload ADC Linker–Payload Conjugation ADC Linker Development Chemical Payload Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Linkers - A Crucial Factor in Antibody–Drug Conjugates Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records:
Send Inquiry
Verification code
Inquiry Basket